Modern therapies targeting the immune synapse. Founded 2015. (NASDAQ:ALPN) Alpine Immune Sciences, (NASDAQ: ALPN) is a development-stage specialty pharmaceutical company, engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases.
In Apr 2017, Nivalis Therapeutics, Inc. (NASDAQ: NVLS) and Alpine Immune, a privately-held company entered into a definitive merger agreement under which Alpine merge with a wholly-owned subsidiary of Nivalis in an all-stock transaction. The merger results in a combined company with a novel protein-based discovery platform focused on inflammation and immuno-oncology.
Alpine was launched in 2015, with series seed financing from Alpine BioVentures, led by Dr. Mitchell H. Gold, Managing Partner, a long?time pioneer in the immuno?oncology area, and Jay Venkatesan, a veteran investor in the biotech space.